Today: 1 July 2026
Browse Category

XRP 14 January 2026 - 25 January 2026

XRP price slips toward $2 as Senate pauses crypto bill vote; Ripple token traders eye Fed next

XRP price slips toward $2 as Senate pauses crypto bill vote; Ripple token traders eye Fed next

NEW YORK, Jan 16, 2026, 14:32 EST — Regular session XRP slipped slightly on Friday, trading just below $2 as investors reacted to a postponed vote in a U.S. Senate committee on a crypto market-structure bill once seen as a crucial near-term indicator for regulatory direction. The token fell around 1.1% to $2.04, putting its market cap near $124 billion, per CoinMarketCap data.
16 January 2026
···
Ripple’s Luxembourg EMI Green Light Puts XRP Back in Focus as EU Crypto Rules Tighten

Ripple’s Luxembourg EMI Green Light Puts XRP Back in Focus as EU Crypto Rules Tighten

Ripple has secured preliminary approval for an electronic money institution license in Luxembourg. This regulatory green light allows the crypto payments company to extend its regulated payment services throughout the European Union from Luxembourg. The timing is crucial. Under the EU’s Markets in Crypto-Assets rules, or MiCA, crypto companies must secure national regulator authorizations to continue operations across the bloc. Regulators are already pressing those who haven’t acted to either apply or close shop. Licenses under MiCA have been handed out to names like U.S. exchange Coinbase, stablecoin issuer Circle, and British fintech Revolut, according to Reuters.
15 January 2026
··
1 … 4 5 6 7 8 … 14

Stock Market Today

  • Kymera Therapeutics (KYMR) up 51% YTD as atopic dermatitis drug hits milestones
    July 1, 2026, 2:57 PM EDT. Kymera Therapeutics (KYMR) is up nearly 51% this year, way ahead of the sector's 6.4%. The stock's gain is tied to progress on KT-621, an oral STAT6 degrader for atopic dermatitis and asthma. Kymera wrapped phase IIb enrollment in the BROADEN2 AD trial six months early, aiming to have the pivotal readout by late 2026. Earlier, phase Ib data showed strong STAT6 knockdown and safety. The FDA put KT-621 on Fast Track for moderate-to-severe AD and eosinophilic asthma. Separately, trials for KT-485, in partnership with Sanofi, led to a $20 million milestone, and Kymera is still developing KT-579. Its alliances with Sanofi and Gilead are part of the company's long-term plans.
Go toTop